Clinical responses to LD IL-2 therapy. (A) Heatmap showing individual clinical responses for patients on a per-organ basis. (B) Summary of organ-specific clinical responses to LD IL-2 therapy. ORR is shown as percentage above bars. Number of patients with individual response (count) are embedded within each bar. (C) Improvement in erythroderma and desquamation after 6 weeks on therapy. (D) Improvement in scleroderma and hyperpigmentation at 14 weeks on therapy. ∗P3 initially started LD IL-2 for liver involvement and subsequently developed pulmonary cGVHD in the setting of pulmonary aspergillosis.